|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 3.** Risk**a** of ≥CIN3, stratified by HPV genotype in subjects with NILM cytology. | | | | | | | |
|  | **Monsonego (2015)**  GO; BL [[28](#_ENREF_28)] | | **Stoler (2019)**  GO; BL [[23](#_ENREF_23)] | | **Schiffman (2015)**  JCM; 16 mo[[30](#_ENREF_30)] | **Berkhof (2006)**  CEBP; 18 mo [[25](#_ENREF_25)] | **Wheeler (2014)**  IJC; 3 yr [[35](#_ENREF_35)] |
| **HPV GT** | 25-29 yrs | ≥30 yrs | ≥25yrs | ≥30 yrs | ≥30 yrs | ≥29 yrs | ≥21 yrs |
| **16** | 11.4 (7.8-16.4) | 8.2 (5.8-11.4) | 8.1 (5.8-10.9) | 6.9 (3.8-10.2) | 10.6 (9.9-11.4) | 17.0 (10.0-26.0) | 2.8 (1.4-4.3) |
| **31** | 6.1 (2.8-12.6) | 4.8 (2.6-8.7) | 7.5 (4.1-11.3) | 8.4 (4.4-13.7) | 4.5 (4.1-5.0) | 7.0 (2.0-19.0) | 1.3 (0.1-2.4) |
| **18** | 2.6 (0.7-9.0) | 4.7 (2.4-9.1) | 2.9 (0.0-6.8) | 2.6 (0.0-6.7) | 5.9 (6.7-9.0) | 9.0 (0.0-30.0) | 0.0 |
| **33** | 14.3 (4.0-39.9) | 1.4 (0.3-7.7) | n/r | n/r | 5.9 (4.8-7.2) | 13.0 (0.0-40.0) | 2.3 (0.0-5.6) |
| **58** | 0.6 (0.1-3.6) | 0.4 (0.1-2.0) | n/r | n/r | 1.4 (1.2-1.6) | 0.0 (0.0-11.0) | 0.0 |
| **33/58** | n/r | n/r | 2.8 (0.6-5.4) | 2.3 (0.0-5.3) | n/r | n/r | n/r |
| **52** | 7.1 (3.6-13.4) | 2.7 (1.3-5.5) | 1.7 (0.4-3.4) | 1.2 (0.0-3.3) | 3.8 (3.4-4.2) | 0.0 (0.0-13.0) | 0.2 (0.0-0.7) |
| **45** | 0.0 (0.0-6.8) | 3.7 (1.6-8.4) | 0.8 (0.0-2.8) | 1.2 (0.0-4.1) | 1.7 (1.4-2.0) | 0.0 (0.0-8.0) | 0.4 (0.0-1.3) |
| **35** | 3.8 (1.1-13.0) | 0.8 (0.1-4.4) | n/r | n/r | 4.1 (3.5-4.9) | 6.0 (0.0-32.0) | 0.0 |
| **39** | 2.6 (0.7-9.0) | 3.1 (1.4-6.6) | n/r | n/r | 0.8 (0.7-1.0) | 0.0 (0.0-17.0) | 0.0 |
| **68** | n/r | n/r | n/r | n/r | 0.7 (0.6-0.9) | 0.0 (0.0-252.0) | 0.0 |
| **35/39/68** | n/r | n/r | 0.7 (0.0-1.7) | 0.7 (0.0-1.9) | n/r | n/r | n/r |
| **51** | n/r | n/r | 1.1 (0.0-3.6) | 1.8 (0.0-5.9) | 1.1 (0.9-1.3) | 0.0 (0.0-13.0) | 0.2 (0.0-0.7) |
| **56** | n/r | n/r | n/r | n/r | 0.8 (0.7-1.0) | 0.0 (0.0-80) | 0 |
| **59** | n/r | n/r | n/r | n/r | 0.6 (0.4-0.7) | 0.0 (0.0-28.0) | 0.4 (0.0-0.9) |
| **66** | n/r | n/r | n/r | n/r | 1.2(1.0-1.5) | 0.0 (0.0-9.0) | n/r |
| **56/59/66** | n/r | n/r | 0.3 (0.0-0.9) | 0.4 (0.0-1.3) | n/r | n/r | n/r |
| **Any HPV pos** | 4.7 (3.5-6.1) | 3.0 (2.4-3.7) | 3.1 (2.5-3.9) | 3.0 (2.1-3.9) | 4.6b | 7.0 (5.0-10.0) | 1.1b |
| **HPV neg** | n/r | n/r | 0.2 (0.0-0.5) | 0.1 (0.0-0.3) | n/r | n/r | <0.1b |
| **Abbreviations:** ≥CIN3, cervical intraepithelial neoplasia, grade 3 or worse; HPV, human papillomavirus; NILM, negative for intraepithelial lesions or malignancies; GT, genotype; yrs, years; n/r, not reported; neg, negative; pos, positive; GO, Gynecologic Oncology; IJC, International Journal of Cancer; CEBP, Cancer Epidemiology, Biomarkers & Prevention; JID, The Journal of Infectious Diseases; JCM, Journal of Clinical Microbiology | | | | | | | |
|  | | | | | | | |
| **a**Risk listed as percent value with corresponding lower and upper confidence intervals in parentheses  b95% confidence interval not listed source article | | | | | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 3 (continued).** Risk**a** of ≥CIN3, stratified by HPV genotype in subjects with NILM cytology result. | | | | | | |
|  | **Schiffman (2016)**  JCM; 16 mo [[31](#_ENREF_31)] | **Thomsen (2015)**  IJC; 4 yr [[34](#_ENREF_34)] | | **Thomsen (2015)**  IJC; 8 yr [[34](#_ENREF_34)] | | **Kjaer (2010)**  JNCI 13.4yr [[27](#_ENREF_27)] |
| **HPV GT** | ≥30 yrs | <30 yrs | ≥30 yrs | <30yrs | ≥30yrs | 20-29 yrs |
| **16** | 13.8 (11.9-15.6) | 8.9 (6.9-10.9) | 11.4 (8.6-14.2) | 21.2 (18.2-24.2) | 21.8 (18.0-25.6) | 26.7 (21.1-31.8) |
| **31** | n/r | 4.9 (2.9-6.8) | 6.3 (3.7-8.9) | 10.9 (7.9-13.9) | 11.3 (7.7-14.9) | 14.3 (9.1-19.4) |
| **18** | n/r | 6.2 (3.4-9.0) | 6.1 (2.6-9.5) | 10.9 (7.1-14.6) | 12.8 (7.6-18.0) | 19.1 (10.4-27.3) |
| **33** | n/r | 7.3 (3.8-10.8) | 8.2 (3.4-13.0) | 11.9 (7.3-16.4) | 12.9 (7.0-18.8) | 14.9 (7.9-21.1) |
| **58** | n/r | n/r | n/r | n/r | n/r | n/r |
| **33/58** | n/r | n/r | n/r | n/r | n/r | n/r |
| **52** | n/r | n/r | n/r | n/r | n/r | n/r |
| **45** | n/r | n/r | n/r | n/r | n/r | n/r |
| **35** | n/r | n/r | n/r | n/r | n/r | n/r |
| **39** | n/r | n/r | n/r | n/r | n/r | n/r |
| **68** | n/r | n/r | n/r | n/r | n/r | n/r |
| **35/39/68** | n/r | n/r | n/r | n/r | n/r | n/r |
| **51** | n/r | n/r | n/r | n/r | n/r | n/r |
| **56** | n/r | n/r | n/r | n/r | n/r | n/r |
| **59** | n/r | n/r | n/r | n/r | n/r | n/r |
| **66** | n/r | n/r | n/r | n/r | n/r | n/r |
| **56/59/66** | n/r | n/r | n/r | n/r | n/r | n/r |
| **Any HPV pos** | n/r | n/r | n/r | n/r | n/r | n/r |
| **HPV neg** | 0.06 (0.05-0.06) | 0.5 (0.3-0.7) | 1.7 (1.4-2.1) | 0.2 (0.1-0.3) | 0.6 (0.34-0.7) | 3.0 (2.5-3.5) |
| Abbreviations: ≥CIN3, cervical intraepithelial neoplasia, grade 3 or worse; HPV, human papillomavirus; GT, genotype; yrs, years; n/r, not reported; neg, negative; pos, positive; IJC, International Journal of Cancer; JCM, Journal of Clinical Microbiology; JNCI, Journal of the National Cancer Institute | | | | | | |
|  | | | | | | |
| **a**Risk listed as percent value with corresponding lower and upper confidence intervals in parentheses | | | | | | |